Kazia Therapeutics
KZIA
7 hedge funds and large institutions have $1.75M invested in Kazia Therapeutics in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 0 closing their positions.
229% more capital invested
Capital invested by funds: $531K → $1.75M (+$1.21M)
17% more funds holding
Funds holding: 6 → 7 (+1)
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$29.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$27.3K |
| 3 |
CWM
Cornerstone Wealth Management
St. Peters,
Missouri
|
+$23.1K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CWM
1
Cornerstone Wealth Management
St. Peters,
Missouri
| $1.43M | +$23.1K | +93 | New |
|
|
2
Morgan Stanley
New York
| $165K | +$29.1K | +117 | +12% |
|
3
Renaissance Technologies
New York
| $102K | – | – | – |
|
4
Acadian Asset Management
Boston,
Massachusetts
| $24K | – | – | – |
|
|
5
UBS Group
Zurich,
Switzerland
| $19K | +$27.3K | +110 | +579% |
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | – | – | – |
|
|
RE
7
RBC Europe
London,
United Kingdom
| $95 | – | – | – |
|
KZIA Hedge Fund Activity: Q2 2018 in Review
7 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Kazia Therapeutics (KZIA) for Q2 2018, worth a combined $1.75M — up 229% from $531K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new KZIA positions and 0 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $29.1K.
- 7 institutional investors held Kazia Therapeutics (KZIA) as of Q2 2018, up from 6 in Q1 2018.
- Funds reported $1.75M of Kazia Therapeutics stock for Q2 2018, up 229% quarter-over-quarter.
- 1 fund opened new Kazia Therapeutics positions in Q2 2018 and 0 closed out, a net change of +1 holder.
- The largest Kazia Therapeutics buyer in Q2 2018 was Morgan Stanley, an estimated $29.1K added.
Based on aggregated 13F filings for Q2 2018.